Rufinamide: A Novel Broad-Spectrum Antiepileptic Drug
2010; SAGE Publishing; Volume: 10; Issue: 1 Linguagem: Inglês
10.1111/j.1535-7511.2009.01336.x
ISSN1535-7597
AutoresJames W. Wheless, Blanca Vázquez,
Tópico(s)Drug Transport and Resistance Mechanisms
ResumoThe last 20 years have witnessed a tremendous explosion in the number of antiepileptic drugs (AEDs) as well as the introduction of AEDS developed for specific epilepsy syndromes. The study of the efficacy and side effect profile of AEDs for unique epilepsy syndromes has allowed neurologists to utilize evidence-based medicine when treating patients. In late 2008, the Food and Drug Administration approved rufinamide for adjunctive use in the treatment of seizures associated with Lennox-Gastaut syndrome. This unique chemical compound is also the first new AED to reach the market in the United States having a pediatric indication prior to approval for adults. Rufinamide appears to have a broad spectrum of efficacy, is well tolerated, and may be rapidly initiated--properties that will likely extend its use outside of Lennox-Gastaut syndrome.
Referência(s)